Biologics as countermeasures for acute radiation syndrome: where are we now?

Despite significant scientific advances toward the development of a safe, nontoxic and effective radiation countermeasure for acute radiation syndrome (ARS) over the past six decades, no drug has been approved by the US FDA. Several biologics are currently under development as radiation countermeasu...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Vijay K, Romaine, Patricia LP, Newman, Victoria L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Informa Healthcare 2015
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720033/
https://www.ncbi.nlm.nih.gov/pubmed/25416452
http://dx.doi.org/10.1517/14712598.2015.986453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720033/
https://www.ncbi.nlm.nih.gov/pubmed/25416452
http://dx.doi.org/10.1517/14712598.2015.986453

Ejemplares similares